%0 Journal Article
%T 术中分子病理指导下的脑胶质瘤诊疗进展<br>Advances in Intraoperative Molecular Pathology-Guided Diagnosis and Treatment of Gliomas
%A 李佳
%A 韩哲
%J Advances in Clinical Medicine
%P 661-672
%@ 2161-8720
%D 2024
%I Hans Publishing
%R 10.12677/acm.2024.1472065
%X 胶质瘤是最常见的恶性脑肿瘤，具有恶性程度高、手术切除困难、术后易复发等特点。随着脑胶质瘤诊疗分子时代的来临，单一的术中组织病理检查已不能满足手术的需求。术中快速获取患者分子突变信息将为胶质瘤的精准分型诊断、指导手术切除及术后辅助治疗提供新的依据。本文对近十年已发表的术中快速分子诊断技术应用于脑胶质瘤的相关研究进行了回顾和梳理，探讨了分子病理指导下成人弥漫性胶质瘤不同分子亚型患者的诊疗特点，并总结了术中辅助识别胶质瘤边界的相关技术，最后对分子病理指导脑胶质瘤切除的应用前景加以展望。<br />
Glioma is the most common intracranial malignant tumor and is recognized as being one of the most difficult tumors to treat because of the difficulty of complete surgical removal and the poor effectiveness of post-operative radiotherapy. With the advent of the molecular era in the diagnosis and treatment of gliomas, a single histopathological examination is no longer sufficient for surgery. The detection of molecular mutation information in patients intraoperatively will provide a new basis for accurate staging and diagnosis of gliomas, guiding surgical resection and postoperative adjuvant therapy. In this paper, we review the published studies on the application of intraoperative rapid molecular diagnosis to glioma in the past decade, summarize the characteristics of the treatment of patients with different glioma subtypes under the guidance of molecular pathology, and finally look forward to the application of molecular pathology to guide the resection of glioma.
%K 脑胶质瘤，IDH突变，TERTp突变，切除范围，肿瘤边界<br>Glioma
%K IDH Mutation
%K TERTp Mutation
%K Extent of Resection
%K Tumor Margins
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=91754